Differential region-specific regulation of central α1- adrenoceptor binding following chronic haloperidol and clozanine administration in the rat

Psychopharmacology

Volumn 172, Issue 2, 2004, Pages 196-201

  Cahir, Marie ^a   Mawhinney, Tim ^a   King, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

1 Adrenoceptor; Clozapine; Haloperidol; Prazosin; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PHENCYCLIDINE; PRAZOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FRONTAL CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SCHIZOPHRENIA; STIMULUS RESPONSE; TISSUE SPECIFICITY;

ANIMALS; BRAIN; CLOZAPINE; HALOPERIDOL; MALE; PRAZOSIN; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 1642368014     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1639-z     Document Type: Article

References (40)

1. Arnsten AF, Steere JC, Hunt RD (1996) The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance for attention deficit hyperactivity disorder. Arch Gen Psychiatry 53:448-455
2. Arnsten AF, Mathew R, Ubriani R, Taylor JR, Li BM (1999) Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 45:26-31
3. Bakshi VP, Geyer MA (1997) Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 283:666-674
4. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen M (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl 17:12-16
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
6. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47:181-188
7. Breier A (1994) Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. J Clin Psychiatry 55:122-125
8. Carasso BS, Bakshi VP, Geyer MA (1998) Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology 37:401-404
9. Chaki S, Funakoshi T, Yoshikawa R, Okuyama S, Kumagai T, Nakazato A, Nagamine M, Tomisawa K (1999) In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology 38:1185-1194
10. Cohen BM, Lipinski JF (1986) In vivo potencies of antipsychotic drugs in blocking alpha-1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci 39:2571-2580
11. Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain. J Neurochem 13:655-669
12. Hancock AA (1996) Alpha-1 adrenoceptor subtypes: a synopsis of their pharmacology and molecular biology. Drug Dev Res 39:54-107
13. Hanft G, Gross G (1989) Subclassification of alpha-1 adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 97:691-700
14. Hommer DW, Zahn TP, Picard D, Van Kammen DP (1984) Prazosin, a specific alpha-1 noradrenergic receptor antagonist has no effect on symptoms but increases autonomic arousal in schizophrenic patients. Psychiatry Res 11:193-204
15. Johnston RD, Iuvone PM, Minneman KP (1987) Regulation of alpha-1 adrenergic receptor density and functional responsiveness in rat brain. J Pharmacol Exp Ther 242:842-849
16. 125I]-HEAT. J Comp Neurol 231:190-208
17. Kane J, Honigfeld G, Siger J, Meltzer H (1988) Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 45:789-796
18. Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition - a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631
19. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2-34
20. Kuoppamaki M, Seppala T, Syvalahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262-1267
21. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropharmacology 13:139-150
22. Mathe JM, Nomikos GG, Hildebrand BE, Hertel P, Svensson TH (1996) Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309:1-11
23. Muller P, Seeman P (1977) Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci 21:1751-1758
24. Nutt DJ, Lalies MD, Lione LA, Hudson AL (1997) Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol 11:163-168
25. O'Malley SS, Chen TB, Francis BE, Gibson RE, Burns HD, DiSalvo J, Bayne ML, Wetzel JM, Nagarathnam D, Marzabadi M, Gluchowski C, Chang RSL (1998) Characterization of specific binding of [125I]L-762,459, a selective alpha-1A adrenoceptor radioligand to rat and human tissues. Eur J Pharmacol 348:287-295
26. Prinssen EPM, Ellenbroek BA, Cools AR (1994) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170
27. Puumala T, Riekkinen P, Sirvio J (1997) Modulation of vigilance and behavioural activation by alpha-1 adrenoceptors in the rat. Pharmacol Biochem Behav 56:705-712
28. Reynolds GP, Garrett N, Rupniak N, Jenner P, Marsden CD (1983) Chronic clozapine treatment of rats downregulates cortical 5-HT2 receptors. Eur J Pharmacol 89:325-326
29. Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197-204
30. Schmidt AW, Lebel LA, Howard HR, Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Psychopharmacol 425:197-201
31. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van-Gompel P, Lesage AS, DeLoore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73
32. Sirvio J, MacDonald E (1999) Central alpha-1 adrenoceptors: their role in the modulation of attention and memory formation. Pharmacol Ther 83:49-65
33. Tarazi FI, Florijn WJ, Creese I (1997a) Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience 78:985-996
34. 4-like dopamine receptors. Neuropsychopharmacology 17:186-196
35. 4-like receptors. Neuroscience 83:169-176
36. Wadenberg M-LG, Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862
37. Wagstaff AJ, Bryson HM (1995) Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant to classical antipsychotic agents. CNS Drugs 4:370-400
38. Westerink BCH, De Boer P, De Vries JB, Kruse C, Long S (1998) Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361:27-33
39. Wilson KM, Minneman KP (1989) Regional variations in alpha-1 adrenergic receptor subtypes in rat brain. J Neurochem 53:1782-1786
40. Yang M, Verfurth F, Buscher R, Michel MC (1997) Is the alpha-1D adrenoceptor protein detectable in rat tissues? Naunyn Schmiedebergs Arch Pharmacol 355:438-446